Cytek Biosciences, Inc.
NASDAQ:CTKBMedical - Devices
-$0.11 today
- Market cap
- $774.24M
- Beta
- 1.19
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$0.57
Volume 1.05M
Average 0.88M
CTKB Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Cytek Biosciences, Inc.NASDAQ: CTKB
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash growth accelerates
Q1 FY2026 net change in cash of $25.19M (cash outflow) rose 630.9% year over year, ahead of the -59.9% change in trailing-twelve-month net change in cash. Sequentially, it rose 937.4% from the prior quarter. Over 3 fiscal years it compounded at -50.5% a year.
Context
- Net change in cash amounted to 3.9% of revenue in FY2025, down 30.4 pp from a year earlier.
- Net change in cash grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +630.9% holds above the trailing-twelve-month pace of -59.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (7.89M) USD
- Year-over-year change
- +88.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.89M) | +88.5% |
| FY2024 | 2024-12-31 | (68.89M) | +47.8% |
| FY2023 | 2023-12-31 | (131.87M) | -102.5% |
| FY2022 | 2022-12-31 | (65.12M) | -132.8% |
| FY2021 | 2021-12-31 | 198.5M | — |
Net Change in Cash vs competitors
How CTKB compares with its peers on the latest reported figures
- CTKB's LTM Mar 2026 net change in cash of $29.63M is the smallest of the 6 companies compared; the peer median is $111.74M.
- Its year-over-year change of -59.9% is the lowest of 6, against a peer median of +220.8%.
- Net change in cash amounts to 14.5% of revenue for CTKB, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $223M | +191.0% | — | 3.0% | |
| LTM Jun 2026 | $144.8M | +502.1% | — | 5.6% | |
| LTM Mar 2026 | $111.74M | +182.9% | — | 129.5% | |
| LTM Jun 2026 | $104.8M | +485.9% | — | 17.0% | |
| LTM Jun 2026 | $93M | +220.8% | — | 2.7% | |
| LTM Mar 2026 | $29.63M | -59.9% | -50.5% | 14.5% | |
| Peer median (excluding CTKB) | $111.74M | +220.8% | — | 5.6% | |
Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 3.03M | 2.48M | (12.15M) | (6.02M) | (66.54M) |
| Depreciation & Amortization | 1.24M | 5.66M | 9.23M | 10.49M | 11.98M |
| Deferred Income Tax | 0 | 0 | 0 | (2.89M) | 33.56M |
| Stock-Based Compensation | 6.59M | 16.6M | 22.05M | 26.85M | 24.59M |
| Change in Working Capital | (8.65M) | (39.93M) | (10.51M) | 7.71M | (4.79M) |
| Accounts Receivables | (12.37M) | (19.74M) | (7.33M) | (5.43M) | 368K |
| Inventory | (7.07M) | (17.65M) | 4.29M | 14.76M | (5.24M) |
| Accounts Payables | (256K) | 1.86M | (1.78M) | 2.58M | 448K |
| Other Working Capital | 11.05M | (4.39M) | (5.68M) | (4.2M) | (366K) |
| Other Non-Cash Items | 2.42M | 2.96M | (3.34M) | (10.77M) | (3.47M) |
| Operating Cash Flow | 4.63M | (12.23M) | 5.28M | 25.38M | (4.69M) |
| Capital Expenditures | (4.36M) | (9.87M) | (4.83M) | (3.53M) | (4.08M) |
| Acquisitions (Net) | (16.63M) | 0 | (45.13M) | (471K) | 252K |
| Purchases of Investments | 0 | (46.04M) | (175.94M) | (274.06M) | (278.16M) |
| Sales of Investments | 0 | 0 | 132M | 195M | 292.21M |
| Other Investing Activities | 0 | (120K) | (179K) | 84K | (107K) |
| Investing Cash Flow | (20.99M) | (55.91M) | (93.89M) | (82.97M) | 10.12M |
| Debt Repayment | (2.77M) | 2.93M | (565K) | 3.62M | 837K |
| Common Stock Issued | 215.69M | 2.79M | 0 | 0 | 1.47M |
| Common Stock Repurchased | 0 | 0 | (44.15M) | (21.61M) | (15.07M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 642K | (209K) | 2.9M | 2.17M | (669K) |
| Financing Cash Flow | 213.56M | 5.51M | (41.81M) | (15.82M) | (13.43M) |
| Effect of Forex Changes | 1.3M | (2.49M) | (1.45M) | 4.53M | 109K |
| Net Change in Cash | 198.5M | (65.12M) | (131.87M) | (68.89M) | (7.89M) |
| Free Cash Flow | 266K | (22.1M) | 454K | 21.85M | (8.77M) |
Cytek Biosciences, Inc.
NASDAQ:CTKB
Intrinsic Alpha fair value
Locked
Current Price
$5.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.